Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

99.50EUR
4:35pm BST
Change (% chg)

€0.48 (+0.48%)
Prev Close
€99.02
Open
€98.86
Day's High
€99.72
Day's Low
€98.04
Volume
483,375
Avg. Vol
459,377
52-wk High
€102.90
52-wk Low
€85.06

Summary

Name Age Since Current Position

Stefan Oschmann

61 2016 Chairman of Executive Board and Chief Executive Officer

Wolfgang Buechele

60 2014 Independent Chairman of the Supervisory Board

Michael Fletterich

61 2014 Independent Vice Chairman of the Supervisory Board, Employee Representative

Marcus Kuhnert

51 2014 Member of the Executive Board, Chief Financial Officer

Udit Batra

48 2016 Chief Executive Officer Life Science, Member of the Executive Board

Kai Beckmann

53 2017 Chief Executive Officer - Performance Materials, Member of the Executive Board

Belen Garijo

58 2015 Chief Executive Officer - Healthcare, Member of the Executive Board

Gabriele Eismann

57 2014 Independent Member of the Supervisory Board, Employee Representative

Edeltraud Glaenzer

63 Independent Member of the Supervisory Board, Employee Representative

Dietmar Oeter

52 2014 Independent Member of the Supervisory Board, Employee Representative

Helga Ruebsamen-Schaeff

70 2014 Independent Member of the Supervisory Board

Juergen Glaser

2019 Member of the Supervisory Board and Employee Representative

Sascha Held

37 Member of the Supervisory Board, Employee Representative

Michael Kleinemeier

62 2019 Member of the Supervisory Board

Renate Koehler

64 2019 Member of the Supervisory Board

Anne Lange

35 2019 Member of the Supervisory Board, Employee Representative

Peter Merck

52 2019 Member of the Supervisory Board

Christian Raabe

55 2019 Member of the Supervisory Board, Employee Representative

Daniel Thelen

44 2019 Member of the Supervisory Board

Simon Thelen

39 2019 Member of the Supervisory Board

Helene von Roeder

49 2019 Member of the Supervisory Board

Biographies

Name Description

Stefan Oschmann

Dr. Stefan Oschmann, Ph.D. is Chairman of Executive Board and Chief Executive Officer at MERCK Kommanditgesellschaft auf Aktien since April 30, 2016. Before taking office at the end of April 2016, he served as Vice Chairman and Deputy CEO, with responsibility for Group Strategy, among other things. Stefan Oschmann joined Merck in 2011 as a member of the Executive Board and was responsible for the Healthcare business sector until the end of 2014. He drove the transformation of the Biopharma business by optimizing its cost structures and improving the efficiency of its research & development model, which included a clear portfolio prioritization. Furthermore, he played an instrumental role in the Group-wide transformation and growth program “Fit for 2018”. Before joining Merck, Stefan Oschmann worked for the U.S. pharma company MSD, where he served in a range of senior executive positions. He started his career at an agency of the United Nations, and worked for the German Chemical Industry Association (VCI). Stefan Oschmann was born in Würzburg, Germany in 1957. He holds a doctorate in Veterinary Medicine from Ludwig-Maximilians-Universität in Munich. He is married and has two children.

Wolfgang Buechele

Dr. Wolfgang Buechele is an Independent Chairman of the Supervisory Board at MERCK Kommanditgesellschaft auf Aktien since May 9, 2014. He was member of Supervisory Board from July 1, 2009 to May 9, 2014. He is Chief Executive Officer of BorsodChem Zrt. He has been Member of the Board of Partners of E. Merck KG since July 1, 2009. He is Member of the Board of Kemira Oij. He is Member of the Finance Committee at the Company.

Michael Fletterich

Mr. Michael Fletterich is Independent Vice Chairman of the Supervisory Board, Employee Representative of MERCK Kommanditgesellschaft auf Aktien since 2014. He was Member of the Supervisory Board and Employee Representative at Merck KGaA since July 1, 1998. He is Chairman of the Works Council of the Gernsheim site of the Company.

Marcus Kuhnert

Mr. Marcus Kuhnert is Member of Executive Board and Chief Financial Officer of Merck KGaA effective August 1, 2014. He has been a member of the Executive Board and Chief Financial Officer of Merck since August 2014. Since September 2017, Marcus Kuhnert additionally took over the responsibility for the newly founded Merck Business Services. He also assumed the accountability for Group Procurement in October 2018. Before joining Merck, he worked for Henkel AG & Co. KGaA, most recently as Chief Financial Officer of the Laundry & Home Care business unit. His previous positions at Henkel included the leadership of the CEO Office and Strategy Development, as well as Corporate Communications ad interim in 2009. From 2007 to 2008, Marcus Kuhnert worked in Singapore as Regional General Manager of Adhesive Technologies for Southeast Asia and played a key role in integrating the largest acquisition in Henkel’s history. Prior to that, he headed Group Financial Statements & Subsidiary Controlling from 2003 to 2006. He began his career at Henkel in Controlling and Investor Relations in 1999. Marcus Kuhnert studied Business Administration and Mechanical Engineering at the Technical University of Darmstadt and graduated with a PhD. He is married and has three children.

Udit Batra

Dr. Udit Batra is Chief Executive Officer Life Science, Member of the Executive Board of MERCK Kommanditgesellschaft auf Aktien since April 30, 2016. He joined the Executive Board of Merck in April 2016. He is responsible for the Life Science business sector, which he has led as CEO since 2014. Prior to that, he was responsible for Merck‘s Consumer Health business. In September 2017, Udit Batra took over Executive Board responsibility for Information Technology. He also oversees the Merck Bioethics Advisory Panel. Before joining Merck in 2011, Udit Batra was Head of Global Public Health and Market Access for Novartis Vaccines & Diagnostics. Prior to that, he served in a range of senior executive positions, including Global Head of Corporate Strategy at Novartis, Switzerland, as well as Country President for the Pharma business of Novartis, Australia. He also held several management positions at the global consultancy McKinsey & Company across the healthcare, consumer and non-profit sectors. Udit Batra started his career as a research engineer at the U.S. pharma company MSD. Udit Batra holds a Ph.D. in Chemical Engineering from Princeton University and a Bachelor of Science in Chemical Engineering from the University of Delaware. He is married and has two children.

Kai Beckmann

Dr. Kai Beckmann is Chief Executive Officer - Performance Materials, Member of the Executive Board of MERCK Kommanditgesellschaft auf Aktien since 2017. He is responsible for the Performance Materials business sector, which he has been leading as CEO since September 2017. In October 2018, Kai Beckmann took also over the responsibility for the Darmstadt site and Inhouse Consulting. In addition, he acts as Country Speaker Germany with responsibility for co-determination matters. Prior to his current role, Kai Beckmann was Chief Administration Officer of Merck with responsibility for Group Human Resources, Group Business Technology, Group Procurement, Inhouse Consulting, Site Operations and Merck Business Services as well as Environment, Health, Safety, Security, Quality. In 2007, he became the first CIO of Merck, with responsibility for Corporate Information Services. From 2004 to 2007, he served as Managing Director of the Merck companies in Singapore and Malaysia, and prior to that he held senior executive responsibility for the Information Management and Consulting unit from 1999 to 2004. He began his career at Merck in 1989 as an IT system consultant.

Belen Garijo

Mrs. Belen Garijo is Chief Executive Officer - Healthcare, Member of the Executive Board of MERCK Kommanditgesellschaft auf Aktien effective January 1, 2015. She has been a member of the Executive Board of Merck since January 2015 as CEO of the Healthcare business sector. She additionally assumed Executive Board responsibility for Group Human Resources in September 2017 and for Environment, Health, Safety, Security, Quality (EQ) in October 2018. Since 2013, she has also served as President and CEO of the Biopharma business, where she joined Merck in 2011 as Chief Operating Officer. Before joining Merck, Belén Garijo served as the Senior Vice President Global Operations Europe at Sanofi-Aventis, where she was also a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer. Prior to that, she worked in R&D for eight years, initially as Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at Abbott headquarters in Illinois, United States.

Gabriele Eismann

Dr. Gabriele Eismann is Independent Member of the Supervisory Board, Employee Representative of MERCK Kommanditgesellschaft auf Aktien since May 9, 2014. He serves as Senior Operational Product Manager. He qualified 1980-1985 Studies in Chemistry, University of Leipzig. 1985 Diploma in Chemistry/Inorganic Analytics, University of Leipzig. 1989 Chemist for Analytics and Spectroscopy, University of Leipzig. 1991 Doctorate (Inorganic and Analytical Chemistry), University of Hannover.

Edeltraud Glaenzer

Ms. Edeltraud Glaenzer is Independent Member of the Supervisory Board, Employee Representative at MERCK Kommanditgesellschaft auf Aktien. She ahs been Vice Chairperson of Industriegewerkschaft Bergbau, Chemie, Energie (IG BCE). She has served as Member of the Supervisory Board of Abbott Management GmbH/Abbott Holding GmbH until January 31, 2009. She is Member of the Board of B. Braun Melsungen AG and Vice Chairman of the Board of Solvay Deutschland GmbH.

Dietmar Oeter

Mr. Dietmar Oeter is Independent Member of the Supervisory Board, Employee Representative of MERCK Kommanditgesellschaft auf Aktien since May 9, 2014. He serves as Head of Corporate Quality Assurance. He is a Full-time member of the works council Darmstadt/Gernsheim of Merck KGaA. His Education: 1991 Diploma in Chemistry, TH Karlsruhe. 1994 Doctorate (Physical Chemistry), University of Tübingen. 2007 MBA (Master of Business Administration) Duke University (Durham, NC, USA), Goethe Business School University of Frankfurt .

Helga Ruebsamen-Schaeff

Prof. Dr. Helga Ruebsamen-Schaeff is an Independent Member of the Supervisory Board of MERCK Kommanditgesellschaft auf Aktien since May 9, 2014. She is Chairperson of the Advisory Board of AiCuris Anti- infective Cures GmbH. She is also member of Research and Development Committee at the company.

Juergen Glaser

Mr. Juergen Glaser is Member of the Supervisory Board and Employee Representative of Merck KGaA since May 1, 2012 till May 9, 2014. He is Regional Director of IG BCE Darmstadt. He qualified 1978-1981 Apprenticeship Chemical Technician, BASF AG Ludwigshafen. 1986-1989 Diploma in Economics, Hochschule für Wirtschaft und Politik Hamburg.

Sascha Held

Mr. Sascha Held is Member of the Supervisory Board, Employee Representative of the Company. His education : 2002–2006 Bachelor of Science (IT), dual study in cooperation with Merck KGaA, Darmstadt, Germany, and University of Applied Sciences Darmstadt 2012 Certification as ITIL V3 Expert.

Michael Kleinemeier

Mr. Michael Kleinemeier is Member of the Supervisory Board of the Company. His Professional career: 1986-1988 System engineer at Krupp Atlas Datensysteme, Essen, Germany. 1989-1999 Several executive level positions within SAP AG including Sales, Consulting and Training. 1999-2001 Member of the Executive Board of Itelligence AG. 2001-2002 Sales Director of the German subsidiary of SAP AG. 2002-2003 Managing Director of the German branch office of SAP AG. 2003-2007 Regional President of the EMEA Central Region, SAP AG. 2007-2008 Member of the Executive Council and Corporate Officer of SAP AG / Head of Industries. 03-08 2008 Co-CEO of Häussler Management Holding Stuttgart, Germany. 2009 Founder of e-mobiligence GmbH. 2010-2012 Regional President of the DACH Region, SAP AG. 2012 President of Global End-to-End Services in parallel to his role as Regional President of the DACH Region and as Corporate Officer, SAP AG. 2013-2014 Regional President of the Middle & Eastern Europe Region, SAP SE; Corporate Officer of SAP AG. Since 2015 Member of the Executive Board of SAP SE, SAP Digital Business Services.

Renate Koehler

Ms. Renate Koehler is Member of the Supervisory Board of the Company. Her Education: 1974-1977 Studies for the higher teaching profession with intermediate examination in biology, chemistry, sports in Gießen, Germany 1977-1981 Pharmacy studies in Freiburg, Germany 1981 Approbation as pharmacist Professional career: 1981-1982 Employed pharmacist in Karlsruhe, Germany. 1983 Employed pharmacist at Engel-Apotheke, Darmsatdt, Germany. 1991 Business takeover of Engel-Apotheke, Darmstadt, Germany. Further board positions: No further mandates Other: Since 2012 Board of Directors Krebshilfe Südhessen e.V.. Since 2015 Member of the Board of Trustees of Bürgerstiftung Darmstadt.

Anne Lange

Ms. Anne Lange is Member of the Supervisory Board, Employee Representative of the Company. Her Education ; Bachelor of Science (process technology), dual study in cooperation with Merck KGaA, Darmstadt, Germany, and University of Applied Sciences, Bingen. Professional career: Merck KGaA, Darmstadt, Germany Since 2006 Application Engineer Performance Materials Pigments. Since 2013 exempt from work full-time as member of works council since 2013.

Peter Merck

Mr. Peter Emanuel Merck is Member of the Supervisory Board of the Company. His Education: 1986-1988 Air force officer 1989-1991 Dresdner Bank, Frankfurt am Main, graduation: banker (Bankkaufmann). 1992-1993 Technical University Darmstadt, study of business informatics, intermediate diploma VWL. 1993-2000 University of Lüneburg, degree in business administration. 2000-2001 Deutscher Golf Verband, Wiesbaden, graduation: golf economist (Golfbetriebswirt).

Christian Raabe

Dr. Christian Raabe is Member of the Supervisory Board, Employee Representative of the Company. His Education: 1983-1988 University degree in Mathematics (minor fields IT and Solid State Physics), University of Darmstadt. 1988-1989 Lectureship in Mathematics, University of Hamburg. 1990 Doctorate (Dr. rer. nat) with specialization in road traffic engineering, University of Darmstadt.

Daniel Thelen

Mr. Daniel Thelen is Member of the Supervisory Board of the Company. His Education: 1995-2000 Law studies, University of Cologne and Université de Lausanne, Switzerland 2001-2004 Legal clerkship, Cologne Higher Regional Court, inter alia Metro AG. 2008-2010 Studies at Bradford University School of Management, Bradford (UK) / Bonn, Degree: Master of Business Administration. Professional career: 2005-2006 Lawyer in the fields of commercial/corporate law, Seitz Partnerschaftsgesellschaft mbB, Cologne, Germany. 2006-2008 Consultant, Lawyer in the fields of insolvencyrestructuring, TMS Restart GmbH, Cologne, Germany. 2008-2010 Senior Consultant, Lawyer in the fields of restructuring, Buchalik Brömmekamp Unternehmensberatung GmbH, Düsseldorf, Germany. 2011-2013 Customer manager for international rail freight transport, DB Netz AG, Headquarters, Frankfurt am Main, Germany.

Simon Thelen

Mr. Simon Thelen is Member of the Supervisory Board of the Company. His Education: 1999-2006 Studies of human medicine in Freiburg i. Br., Pamplona (Spain) and Cologne. 2006 State examination in human medicine and licensure as a physician. 2007 Doctorate (Dr. med.) at the Medical Faculty of the University of Cologne . Clinic for Trauma and Hand Surgery and Clinic for Orthopaedics, University Hospital Düsseldorf (UKD). 2006-2014 Research Assistant/Assistant Doctor/Specialist Doctor. 2013 Specialist in orthopaedics and trauma surgery. Since 10/2014 Senior physician at the clinic for trauma and hand surgery, UKD. 2015 Specialist additional designation special trauma surgery. 2018 Specialist additional qualification in hand surgery. Medical Faculty of the Heinrich Heine University Düsseldorf 2015 Habilitation (private lecturer) in orthopaedics and trauma surgery and teaching activities.

Helene von Roeder

Ms. Helene von Roeder is Member of the Supervisory Board of the Company. Her Education: 1989-1993 Study of theoretical physics, Ludwig-MaximilianUniversität München 1993-1994 Study of theoretical astrophysics, University of Cambridge. Professional career: 1995-2000 Deutsche Bank AG, London, UK. 2000-2004 UBS AG, Frankfurt am Main, Germany and London, UK. 2004-2014 Morgan Stanley Bank AG, Frankfurt am Main – most recently member of the Executive Board of Morgan Stanley Bank AG and Head of Global Capital Markets for Germany and Austria 2014-2018 Credit Suisse – CEO Germany, responsible for the business of Credit Suisse in Germany, Austria and CEE. Since 2018 Vonovia SE – Member of the Executive Board (CFO), responsible for Controlling, Finance, Accounting, Tax, Valuation, Procurement, Insurance and Third Party Management.